277 related articles for article (PubMed ID: 31341415)
1. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
2. Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Teng C; Baus C; Wilson JP; Frei CR
Int J Med Sci; 2019; 16(11):1504-1509. PubMed ID: 31673242
[No Abstract] [Full Text] [Related]
3. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
Diaby V; Almutairi RD; Chen Z; Moussa RK; Berthe A
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):159-168. PubMed ID: 33186061
[No Abstract] [Full Text] [Related]
4. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Patek TM; Teng C; Kennedy KE; Alvarez CA; Frei CR
Drug Saf; 2020 Jan; 43(1):17-22. PubMed ID: 31691256
[TBL] [Abstract][Full Text] [Related]
5. Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System.
Shao H; Shi D; Dai Y
Br J Clin Pharmacol; 2023 Apr; 89(4):1386-1392. PubMed ID: 36346345
[TBL] [Abstract][Full Text] [Related]
6. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
7. Association of Torsade de Pointes and QT Prolongation With Antifungal Triazoles: Analysis Using a Pharmacovigilance Database.
Ohyama K; Akiyama S; Iida M; Hori Y
In Vivo; 2023; 37(6):2719-2725. PubMed ID: 37905641
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.
Poluzzi E; Raschi E; Motola D; Moretti U; De Ponti F
Drug Saf; 2010 Apr; 33(4):303-14. PubMed ID: 20297862
[TBL] [Abstract][Full Text] [Related]
9. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
10. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
11. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.
Sessler NE; Walker E; Chickballapur H; Kacholakalayil J; Coplan PM
Postgrad Med; 2017 Jan; 129(1):62-68. PubMed ID: 27977317
[TBL] [Abstract][Full Text] [Related]
12. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
Meyer-Massetti C; Cheng CM; Sharpe BA; Meier CR; Guglielmo BJ
J Hosp Med; 2010 Apr; 5(4):E8-16. PubMed ID: 20394022
[TBL] [Abstract][Full Text] [Related]
13.
Teng C; Reveles KR; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(5):630-635. PubMed ID: 31217729
[No Abstract] [Full Text] [Related]
14. Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol.
Woosley RD; Romero K; Heise CW; Gallo T; Tate J; Woosley RL
Drug Saf; 2019 Jul; 42(7):907-913. PubMed ID: 30888625
[TBL] [Abstract][Full Text] [Related]
15. A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system.
Yan Y; Wu B; Wang L
Expert Opin Drug Saf; 2024 Mar; ():1-8. PubMed ID: 38482864
[TBL] [Abstract][Full Text] [Related]
16. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
[TBL] [Abstract][Full Text] [Related]
18. Torsade de Pointes/QT Prolongation Associated with Antifungal Triazoles: A Pharmacovigilance Study Based on the U.S. FDA Adverse Event Reporting System（FAERS）.
Yu Z; Liao X
J Pharm Pharm Sci; 2022; 25():237-243. PubMed ID: 35790147
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
